We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+10.92%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$657M
AUM Growth
-$6.71M
Cap. Flow
+$44.5M
Cap. Flow %
6.78%
Top 10 Hldgs %
66.42%
Holding
38
New
3
Increased
16
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$24.1M
2
ELVN icon
Enliven Therapeutics
ELVN
+$22.5M
3
VERA icon
Vera Therapeutics
VERA
+$21.8M
4
AKRO
Akero Therapeutics
AKRO
+$11.3M
5
BLU
BELLUS Health Inc.
BLU
+$9.9M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$29.7M
2
ACLX
Arcellx
ACLX
+$18.3M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$15.8M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$13.3M
5
ETNB
89bio
ETNB
+$9.65M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
26
Aclaris Therapeutics
ACRS
$730M
$5.14M 0.78%
635,000
-1,245,286
-66% -$15.8M
THRD
27
DELISTED
Third Harmonic Bio
THRD
$4.09M 0.62%
993,294
– –
ADVM
28
DELISTED
Adverum Biotechnologies
ADVM
$3.59M 0.55%
+500,000
New +$3.54M
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
$2.46M 0.37%
312,553
– –
RZLT icon
30
Rezolute
RZLT
$480M
$1.72M 0.26%
898,267
-311,733
-26% -$702K
ABOS icon
31
Acumen Pharmaceuticals
ABOS
$154M
$1.62M 0.25%
400,000
-98,315
-20% -$513K
DBVT
32
DBV Technologies
DBVT
$807M
$157K 0.02%
9,269
– –
ACLX
33
DELISTED
Arcellx
ACLX
– –
-591,437
Closed -$18.3M
ETNB
34
DELISTED
89bio
ETNB
– –
-758,244
Closed -$9.65M
FDMT icon
35
4D Molecular Therapeutics
FDMT
$526M
– –
-598,385
Closed -$13.3M
IMUX icon
36
Immunic
IMUX
$182M
– –
-180,000
Closed -$2.52M
KPTI icon
37
Karyopharm Therapeutics
KPTI
$168M
– –
-129,041
Closed -$6.58M
LRMR icon
38
Larimar Therapeutics
LRMR
$416M
– –
-750,000
Closed -$3.1M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Commodore Capital held 38 positions worth $657M, down 1% from $664M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Commodore Capital deployed $44.5M of net new capital in Q1 2023, opening 3 new positions and adding to 16 existing holdings. Its largest new stake was Ambrx Biopharma Inc: 4,803,447 shares worth $42.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $29.7M trimmed.

  • Commodore Capital's largest Q1 2023 buy was Ambrx Biopharma Inc: 4,803,447 shares worth $42.8M.
  • Commodore Capital added most to Enliven Therapeutics in Q1 2023, an estimated $22.5M increase.
  • Commodore Capital's biggest Q1 2023 reduction was Cymabay Therapeutics, cutting an estimated $29.7M.
  • Commodore Capital fully exited Arcellx in Q1 2023, selling an estimated $18.3M.
  • Commodore Capital's ten largest holdings make up 66% of its $657M portfolio in Q1 2023.
  • Commodore Capital opened 3 new positions and closed 6 in Q1 2023.
  • Commodore Capital's portfolio value fell 1% quarter-over-quarter to $657M.

Based on Commodore Capital's 13F filing for Q1 2023, filed 15 May 2023.